



Treatment of very elderly glioblastoma patients ≥ 75 years of age: whom to treat

Peter Baumgarten^{1,11} · Georg Prange² · Marcel A. Kamp^{2,12} · Daniel Monden^{2,13} · Vanessa Neef³ · Franziska Schwarzer¹ · Daniel Dubinski^{1,14} · Nazife Dinc^{1,2} · Katharina J. Weber^{4,7,8,9,10} · Markus Czabanka¹ · Elke Hattingen⁵ · Michael W. Ronellenfitsch⁶ · Joachim P. Steinbach⁶ · Christian Senft^{1,11}

Received: 9 October 2023 / Accepted: 20 November 2023
© The Author(s) 2023

Abstract

Purpose The prognosis of patients ≥ 75 years suffering from glioblastoma is poor. Novel therapies are usually reserved for patients ≤ 70 years. In an aging population, treatment of very elderly patients remains a challenge.

Methods Between 2010 and 2018, a total of 977 glioblastoma patients were treated at our institution. Of these, 143 patients were ≥ 75 years at diagnosis. Primary procedure was surgical resection or biopsy followed by adjuvant treatment, whenever possible. We retrospectively investigated overall survival (OS) and potential prognostic factors influencing survival, including Karnofsky Performance Status (KPS), surgical therapy, adjuvant therapy as well as MGMT promotor status.

Results In very elderly patients, median age was 79 years (range: 75–110). Biopsy only was performed in 104 patients; resection was performed in 39 patients. Median OS for the entire cohort was 5.9 months. Univariate analysis showed that KPS at presentation (≥ 70 vs. ≤ 60), surgery vs. biopsy, adjuvant chemotherapy and adjuvant radiotherapy were significantly associated with OS (6 vs. 3, $p < 0.0111$; 12 vs. 4, $p = 0.0011$; 11 vs. 4, $p = 0.0003$ and 10 vs. 1.5 months, $p < 0.0001$, respectively). Multivariate analysis confirmed adjuvant radiotherapy ($p < 0.0001$) and chemotherapy ($p = 0.0002$) as independent factors influencing OS.

Conclusion For very elderly patients, the natural course of disease without treatment is devastating. These patients benefit from multimodal treatment including adjuvant radiotherapy and chemotherapy. A beneficial effect of resection has not been demonstrated. Treatment options and outcomes should be thoughtfully discussed before treatment decisions are made.

Keywords Elderly · Glioblastoma · Glioma · Very elderly

✉ Peter Baumgarten
peter.baumgarten@med.uni-jena.de

¹ Department of Neurosurgery, University Hospital Frankfurt, Goethe University, Frankfurt, Germany

² Department of Neurosurgery, University Hospital Jena, Friedrich Schiller University, Jena, Germany

³ Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Goethe University, Frankfurt, Germany

⁴ Neurological Institute (Edinger Institute), University Hospital Frankfurt, Goethe University, Frankfurt, Germany

⁵ Department of Neuroradiology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany

⁶ Department of Neuro-Oncology, University Hospital Frankfurt – Goethe-University, Frankfurt, Germany

⁷ German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, Frankfurt, Germany

⁸ German Cancer Research Center (DKFZ), Heidelberg, Germany

⁹ Frankfurt Cancer Institute (FCI), Goethe University, Frankfurt, Germany

¹⁰ University Cancer Center (UCT), Goethe University Hospital, Frankfurt, Germany

¹¹ Present address: Department of Neurosurgery, University Hospital Jena, Friedrich Schiller University, Am Klinikum 1, D-07747 Jena, Germany

¹² Present address: Centre for Palliative and Neuro-palliative Care, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Campus Rüdersdorf, Rüdersdorf bei Berlin, Germany

¹³ Present address: Department of Neurosurgery, Hannover Medical School, Hannover, Germany

¹⁴ Present address: Department of Neurosurgery, University Medicine Rostock, Rostock, Germany

Introduction

Glioblastoma is the most frequent malignant brain tumor with a poor prognosis even in younger patients [1]. Common treatment strategies include neurosurgical tumor resection followed by concomitant and adjuvant radiotherapy either with temozolomide according to the European Organization for Research and Treatment of Cancer (EORTC)-22,981/26,981 / National Cancer Institute of Canada (NCIC) CE3 trial [1, 2]. Although patients > 70 years of age were excluded in this pivotal trial, benefit of therapy is conveyed in elderly patients as well: the prospective NOA-08, Nordic and the CCTG CE.6/EORTC 26,062 – 22,061 phase III trials addressed less aggressive treatment protocols in an elderly glioblastoma patient population [3–5]. Among other things, these studies established the value of O6-methylguanine-DNA methyltransferase (*MGMT*) promoter methylation status as a prognostic and therapeutic marker. Recent guidelines, such as the European Association for Neuro-Oncology (EANO) guideline, recommended to treat IDH-wildtype glioblastoma patients ≥ 70 years with surgery followed by hypofractionated radiotherapy for *MGMT*-promoter-unmethylated tumours and followed by the standard concomitant and adjuvant radiotherapy with temozolomide or temozolomide alone [6]. However, optimal treatment of elderly glioblastoma patients is still a matter of debate.

Aim of the present retrospective study was to establish outcome data in a non-selected cohort of elderly patients and to identify prognostic factors for this patient subgroup.

Materials and methods

Patients

We retrospectively analyzed 977 patients treated surgically for the former diagnosis “glioblastoma, WHO grade IV”, in our hospital, between 01/2010 and 12/2018. Surgical treatment was defined as either resection, biopsy or biopsy followed by resection. Treatment for recurrent tumor was reported as well. Histological diagnosis was confirmed by at least two board certified neuropathologists following standard HE stains and immunohistochemical staining for glial fiber acidic protein (GFAP) and Ki67 antigen, according to the then current WHO classification [1]. Methylation specific polymerase chain reaction (mPCR) for the *MGMT* promoter was performed in all primary cases following routine protocols. *MGMT*-promoter methylation was either stated as “methylated”, “not methylated” or “not conclusive” if mPCR did not show conclusive results with good positive and negative control in two runs with patient material.

Patient data was retrieved from the electronic patient reports.

Outcome parameters

All MRI images were obtained by contrast-enhanced 1.5T or 3T MRI. For detection of tumor and tumor progression, non-contrast-enhanced and contrast-enhanced T1, T2-weighted, diffusion weighted imaging and fluid attenuated inversion recovery sequences were evaluated. Both, a senior neurosurgeon and neuroradiologist independently evaluated the MR scans. A tumour in-brain progression was diagnosed according to the Response Assessment in Neuro-Oncology (RANO) criteria [7].

All patients were routinely followed in regular 3-month intervals or shorter, if recommended by our institutional multidisciplinary neurooncology tumor board. General clinical performance was assessed according to Karnofsky Performance Status (KPS) [8, 9]. Treatment decisions were made according to patients' preferences following tumor board recommendation.

Overall survival was defined as time span from confirmation of the histopathological diagnosis (i.e. date of biopsy or tumor resection) until death due to any cause.

Statistical analyses

For statistical analyses, patients younger than 75 years of age were excluded. Statistical analysis and figure editing were performed using JMP 14.0 software (SAS, Cary, NC, USA), GraphPad Prism 6 (GraphPad Software Inc., La Jolla, USA) and Gimp2. Survival analyses were performed using Kaplan-Meier analyses. For evaluation of KPS the patient cohort was dichotomized between good and poor status with a cutoff at $\geq 70\%$. For Kaplan-Meier survival analyses we used Wilcoxon and Log-rank test. For multivariate analyses a proportional hazard ratio was calculated. To compare ratios in different groups, likelihood-ratio and Pearson χ^2 were applied. To compare KPS in different treatment groups, MannWhitney U test was used for non-parametric testing. Significance level alpha was set as $p \leq 0.05$ for all tests.

Ethics

The study was approved by the ethics committee of the university hospital of Frankfurt and the University Cancer Center (UCT) Frankfurt/Main (EC number 4/09, project ethical vote SNO_15_2019).

Results

Patient population

Of a total of 977 patients, 143 patients were 75 years or older at primary surgery and thus defined as very elderly. In very elderly patients, median age was 79 years (range: 75–110). The data describing the cohort in the primary situation is summarized in Table 1. Sex, MGMT promoter methylation status and the admission of chemotherapy was equally distributed in the resection and biopsy only group. Preoperative KPS $\geq 70\%$ and the probability to receive adjuvant irradiation were significantly higher in the resection group (Table 1).

Influence of resection, adjuvant chemotherapy, irradiation and preoperative Karnofsky performance scale score (KPS) on overall survival (OS)

Comparing patients who underwent resection or resection after biopsy in the primary situation ($n=39$) with patients without resection but biopsy only ($n=104$), patients undergoing microsurgical resection showed significantly longer OS than patients receiving biopsy only (median survival 12 vs. 4 months, Wilcoxon $p=0.0002$, Log Rank $p=0.0011$; Fig. 1A). Patients who received adjuvant chemotherapy after resection or biopsy showed significantly longer OS than patients without ($n=48$ vs. 70; median survival 11 vs. 4 months, Wilcoxon $p<0.0001$, Log Rank $p=0.0003$; Fig. 1B). In the same context, adjuvant irradiation after resection or biopsy was associated with significantly longer OS ($n=76$ vs. 40; median survival 10 vs. 1.5 months, Wilcoxon $p<0.0001$, Log Rank $p<0.0001$; Fig. 1C). Preoperative

KPS was dichotomized at $\geq 70\%$ / $<70\%$. Patients in the group with higher preoperative KPS showed a significantly higher OS in our cohort ($n=77$ vs. 66; median survival 6 vs. 3 months, Wilcoxon $p<0.0036$, Log Rank $p<0.0111$; Fig. 1D).

Multivariate survival analyses

In multivariate analyses we compared the effects of surgical treatment, chemotherapy, irradiation and preoperative KPS (Table 2). Independent factors influencing OS were adjuvant irradiation ($p<0.0001$) and adjuvant chemotherapy ($p=0.0002$) but not preoperative KPS or surgical treatment.

Distribution of Karnofsky Performance Status (KPS) in the different treatment groups

KPS was significantly higher in more aggressive treatment regimens: Patients with microsurgical resection showed higher KPS than those with biopsy only (Mann-Whitney U test, $p=0.0045$, Fig. 2A), same as patients with adjuvant chemotherapy (Mann-Whitney test, $p=0.0001$, Fig. 2B) or adjuvant irradiation (Mann-Whitney U test, $p<0.0001$, Fig. 2C). Higher KPS was further associated with any adjuvant therapy as compared to no adjuvant therapy (Mann-Whitney U test, $p<0.0001$, Fig. 2D).

Discussion

The present study represents one of the largest series of non-selected very elderly glioblastoma patients reported so far. We identified adjuvant irradiation and chemotherapy

Table 1 Summary of patient characteristics

| | Biopsy only | Resection | Total | <i>p</i> -Value |
|-----------------------|-------------|------------|------------|--------------------|
| | 104 (72.7%) | 39 (27.3%) | 143 | log-rank / Pearson |
| Gender | | | 143 | 0.8369 / 0.8368 |
| - male | 58 (55.8%) | 21 (53.8%) | 79 (55.2%) | |
| - female | 46 (44.2%) | 18 (46.2%) | 64 (44.8%) | |
| KPS preopative | | | 143 | 0.0021 / 0.0026 ** |
| - ≥ 70 | 48 (46.2%) | 29 (74.4%) | 77 (53.8%) | |
| - < 70 | 56 (53.8%) | 10 (25.6%) | 66 (46.2%) | |
| MGMT | | | 109 | 0.5423 / 0.5423 |
| - methylated | 28 (38.4%) | 16 (44.4%) | 44 (40.4%) | |
| - unmethylated | 45 (61.6%) | 20 (55.6%) | 65 (59.6%) | |
| - inconclusive | 31 | 3 | 34 | |
| Chemotherapy | | | 118 | 0.1244 / 0.1226 |
| - yes | 30 (36.1%) | 18 (51.4%) | 48 (40.7%) | |
| - no | 53 (63.9%) | 17 (48.6%) | 70 (59.3%) | |
| Irradiation | | | 116 | 0.0073 / 0.0098 ** |
| - yes | 47 (58.0%) | 29 (82.9%) | 76 (65.5%) | |
| - no | 34 (42.0%) | 6 (17.1%) | 40 (34.5%) | |




Fig. 1 Comparison of overall survival (OS) (A) Biopsy alone vs. tumor resection (B) No chemotherapy vs. chemotherapy (C) No radiotherapy vs. radiotherapy (D) Preoperative KPS ≥ 70 vs. < 70

Table 2 Multivariate analyses regarding the effects of surgical treatment, adjuvant chemotherapy, adjuvant irradiation and preoperative KPS on OS

| | No. Parameters | Likelihood Ratio Chi ² | Probability > Chi ² |
|------------------------------|----------------|-----------------------------------|--------------------------------|
| Adjuvant Irradiation | 1 | 21.3233135 | <0.0001 |
| Adjuvant Chemotherapy | 1 | 14.022966 | 0.0002 |
| Preoperative KPS $\geq 70\%$ | 1 | 0.93978041 | 0.3323 |
| Resection vs. Biopsy | 1 | 2.25067413 | 0.1336 |

as favorable independent factors for the overall survival in very elderly patients.

Although glioblastoma is common in elderly patients, standard therapy has long been defined only for patients under 65 or under 70 years of age. Additionally, the age cut-off for several studies on therapy for glioblastoma in the elderly is set at 65 years [3, 5, 10–13]. Different prospective and randomized trials documented the benefit of complete surgical resection if at the same time new perioperative deficits can be avoided [14–17]. Based on the EORTC-22,981/26,981 / NCIC CE3 trial, standard adjuvant therapy is an adjuvant and concomitant radio-/chemotherapy with temozolomide [2]. For MGMT promoter methylated glioblastomas, intensification of temozolomide chemotherapy by additional administration of CCNU might be beneficial [18]. Interestingly, there were no relevant differences in the distribution of MGMT promoter methylation status in our elderly cohort compared to other studies with a younger

patient cohort [3–5]. Based on the (EORTC)-22,981/26,981 / National Cancer Institute of Canada (NCIC) CE3 study, it was assumed that standard therapy is too aggressive for elderly patients, and less aggressive adjuvant therapy concepts were addressed in prospective studies [19].

The NOA-08 trial compared temozolomide chemotherapy alone (100 mg/m² temozolomide, one week on / one week off protocol) with radiotherapy alone (30 \times 1.8–2.0 Gy ad 60 Gy) in glioblastoma patients with a KPS > 50 and an age > 65 years. The study established the MGMT promoter methylation as therapeutic marker as temozolomide chemotherapy was associated with a longer event-free survival in MGMT promoter methylated glioblastoma as compared to radiation therapy alone. In contrast, in MGMT promoter unmethylated glioblastoma, radiation was beneficial [3]. The Nordic trial compared temozolomide chemotherapy alone (200 mg/m²; 5/28 day cycle), radiation therapy (30 \times 2 Gy ad 60 Gy) and hypofractionated radiotherapy (10 \times 3.4 Gy ad 34 Gy) in elderly glioblastoma patients ≥ 60 years. The study confirmed the role of the MGMT as therapeutic marker as the overall survival was not inferior in the temozolomide chemotherapy group compared to standard radiation therapy [5]. The CCTG CE.6/EORTC 26,062 – 22,061 phase III trial compared hypofractionated radiotherapy (40 Gy/15 fractions) alone with hypofractionated radiotherapy with concomitant and adjuvant temozolomide in newly diagnosed glioblastoma patients aged ≥ 65 years [4].




Fig. 2 Comparison of Karnofsky Performance Status (KPS) (A) Biopsy alone vs. tumor resection (B) No chemotherapy vs. chemotherapy (C) No radiotherapy vs. radiotherapy (D) No adjuvant therapy vs. any adjuvant therapy

In our present analysis Kaplan-Meier analyses suggested that aggressive neurosurgical treatment with resection instead of biopsy alone was associated with favorable outcome referred to overall survival (OS). In contrast, our multivariate analysis showed no benefit in terms of the overall survival for a surgical resection. Again, although prospective and randomized trials have proven the benefit of a complete surgical resection if at the same time new perioperative deficits can be avoided [14–17], such an association has yet not been shown for elderly and geriatric patients. With reference to the ANOCEF trial from 2022, no advantage was demonstrated for tumor resection compared to biopsy alone in patients ≥ 70 years of age in terms of OS. However, there was a significantly better quality of life and PFS for patients following tumor resection [20]. Here, multimorbidity and geriatric limitations could certainly be risk factors for successful surgery. The benefit of a complete resection may not outweigh the increased risk from multimorbidity and geriatric limitations. However, with our data this remains speculative since co-morbidities weren't systematically recorded. Further prospective and randomized studies assessing the role of surgical and novel adjuvant treatments in geriatric glioblastoma patients are needed.

Independent of the prospective studies on adjuvant therapy in elderly glioblastoma patients mentioned above, the impact of the adjuvant therapy has been analyzed in numerous retrospective studies [21–31]. Elderly patients in good pre- and postoperative clinical condition may have comparable survival rates as younger patients when treated according to standard of care [32]. However, a more aggressive therapy likely results in a higher frequency of side-effects and clinical deterioration. The predictive role of MGMT promoter methylation is well documented in various studies and should therefore be considered [32, 33].

In our cohort, the natural course of the disease proved to be devastating, especially when biopsy without adjuvant treatment was performed. A more aggressive therapy resulted in a better outcome as defined by a longer overall survival, albeit this also being short. However, it should be considered in this context that aggressive treatments can only be offered to patients with a good general condition, guided by the KPS. Our results may help clinicians to counsel their patients regarding the pros and cons of surgery and/or adjuvant therapy.

Limitations

We acknowledge several limitations of our analysis: (1) All data are derived from a retrospective, single center study. (2) A standard geriatric assessment was neither established in the present study nor in recent prospective randomized trials [3]. Like the general condition as assessed by the KPS, however, geriatric burden most likely has an impact on the ability to cope with surgical and adjuvant therapy, on the quality of life and on the prognosis. Therefore, a high symptom burden in geriatric screening could be a valuable marker for therapy decisions. (3) In the present series, we analysed a homogenous cohort with elderly IDH-wildtype glioblastoma patients and aimed to minimize potential confounders by different brain tumours diagnoses. As a potential confounder, the patient cohort was heterogenous in respect to pre-therapeutic clinical performance and therapeutic protocols, making estimates regarding their effect on overall survival difficult. (4) Tumors were histopathologically classified by the 2016 version of WHO classification. Recently, a new version of the WHO classification was published. However, the differences between versions of the WHO classification can be regarded as rather small with regard to IDH wild-type glioblastomas. Moreover, new and more aggressive therapies of glioblastomas have been introduced, e.g. the adjuvant and concomitant temozolomide and CCNU chemotherapy for patients with MGMT promoter methylated glioblastoma [18] as well as the tumour-treating fields [34]. The impact of the therapies in the treatment of especially elderly patients remains yet unclear. (5) In the present analysis, we did not analyse the side effects, such as hemato-toxicity or treatment effects on neurocognition. (6) Moreover, we did not perform any assessment of quality of life, psycho-oncological and social burden on patients and their relatives. We cannot exclude that the identified prognostic markers might significantly impair patient's quality of life. This issue might be addressed in further studies.

Conclusion

The overall outcome of very elderly patients with glioblastoma is limited. In the present study, we identified adjuvant irradiation and chemotherapy as favorable independent factors on overall survival in very elderly patients age ≥ 75 years. In contrast, surgical resection was not associated with improved survival in multivariable analysis. Future studies should analyze the impact of novel adjuvant treatments as well as the impact of geriatric burden and impairment on overall survival and quality of life in elderly glioblastoma patients.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s11060-023-04518-w>.

Authors' contributions All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by P.B., G.P. and C.S. The first draft of the manuscript was written by P.B. and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding KJW was funded by the Mildred Scheel Career Center Frankfurt (Deutsche Krebshilfe). Open Access funding enabled and organized by Projekt DEAL.

Data Availability The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval The study was approved by the ethics committee of the university hospital of Frankfurt and the University Cancer Center (UCT) Frankfurt/Main (EC number 4/09, project ethical vote SNO_15_2019).

Conflict of Interest The authors have no relevant financial or non-financial interests to disclose.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathol* 131:803–820
2. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med*. <https://doi.org/10.1056/NEJMoa043330>
3. Wick W, Platten M, Meisner C et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. *Lancet Oncol* 13. [https://doi.org/10.1016/S1470-2045\(12\)70164-X](https://doi.org/10.1016/S1470-2045(12)70164-X)
4. Perry JR, Laperriere N, O'Callaghan CJ et al (2016) A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062 – 22061, TROG 08.02, NCT00482677). *J Clin Oncol* 34. https://doi.org/10.1200/jco.2016.34.18_suppl.lba2
5. Malmström A, Grønberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated

- radiotherapy in patients older than 60 years with glioblastoma: the nordic randomised, phase 3 trial. *Lancet Oncol* 13. [https://doi.org/10.1016/S1470-2045\(12\)70265-6](https://doi.org/10.1016/S1470-2045(12)70265-6)
6. Weller M, van den Bent M, Preusser M et al (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. *Nat Rev Clin Oncol* 18. <https://doi.org/10.1038/s41571-020-00447-z>
7. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. *J Clin Oncol* 28:1963–1972. <https://doi.org/10.1200/JCO.2009.26.3541>
8. Karnofsky D, Burchenal J (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: Evaluation of chemotherapeutic agents
9. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH (1948) The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma. <https://doi.org/10.1002/1097-0142%28194811%291:4%3C634::AID-CNCR2820010410%3E3.0.CO%3B2-L>. *Cancer* 1:
10. Schwartz C, Romagna A, Stefanits H et al (2020) Risks and benefits of Glioblastoma Resection in older adults: a retrospective Austrian Multicenter Study. <https://doi.org/10.1016/j.wneu.2019.09.097>. *World Neurosurg*
11. Wick A, Kessler T, Elia AEH et al (2018) Glioblastoma in elderly patients: solid conclusions built on shifting sand? <https://doi.org/10.1093/neuonc/nox133>. *Neuro Oncol*
12. Keime-Guibert F, Chinot O, Taillandier L et al (2007) Radiotherapy for Glioblastoma in the Elderly. *N Engl J Med* 356. <https://doi.org/10.1056/nejmoa065901>
13. Perry JR, Laperriere N, O'Callaghan CJ et al (2017) Short-course Radiation plus Temozolomide in Elderly patients with Glioblastoma. *N Engl J Med* 376. <https://doi.org/10.1056/nejmoa1611977>
14. Stummer W, Reulen HJ, Meinel T et al (2008) Extent of resection and survival in Glioblastoma Multiforme: identification of and adjustment for bias. *Neurosurgery* 62. <https://doi.org/10.1227/01.neu.0000317304.31579.17>
15. Stummer W, Pichlmeier U, Meinel T et al (2006) Fluorescence-guided Surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. *Lancet Oncol* 7. [https://doi.org/10.1016/S1470-2045\(06\)70665-9](https://doi.org/10.1016/S1470-2045(06)70665-9)
16. Oszvald Á, Güresir E, Setzer M et al (2012) Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age: clinical article. *J Neurosurg* 116:357–364. <https://doi.org/10.3171/2011.8.JNS102114>
17. Stummer W, Kamp MA (2009) The importance of surgical resection in malignant glioma. *Curr Opin Neurol* 22:645–649
18. Herrlinger U, Tzaridis T, Mack F et al (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. *The Lancet*. [https://doi.org/10.1016/S0140-6736\(18\)31791-4](https://doi.org/10.1016/S0140-6736(18)31791-4). 393:
19. Mirmanoff RO, Gorlia T, Mason W et al (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. *J Clin Oncol* 24:2563–2569. <https://doi.org/10.1200/JCO.2005.04.5963>
20. Laigle-Donadey F, Metellus P, Guyotat J et al (2023) Surgery for glioblastomas in the elderly: an Association Des Neuro-oncologues d'Expression Française (ANOCEF) trial. *J Neurosurg* 138:1199–1205. <https://doi.org/10.3171/2022.8.JNS221068>
21. Lu VM, Kerezoudis P, Brown DA et al (2019) Hypofractionated versus standard radiation therapy in combination with temozolomide for glioblastoma in the elderly: a meta-analysis. *J Neurooncol*
22. Palmer JD, Bhamidipati D, Mehta M et al (2018) Treatment recommendations for elderly patients with newly diagnosed glioblastoma lack worldwide consensus. *J Neurooncol*. <https://doi.org/10.1007/s11060-018-2969-3>
23. Harrison RA, de Groot JF (2018) Treatment of Glioblastoma in the Elderly. *Drugs Aging* 35:707–718
24. Karsy M, Yoon N, Boettcher L et al (2018) Surgical treatment of glioblastoma in the elderly: the impact of Complications. *J Neurooncol* 138. <https://doi.org/10.1007/s11060-018-2777-9>
25. Okada M, Miyake K, Tamiya T (2017) Glioblastoma treatment in the elderly. *Neurol Med Chir (Tokyo)* 57:667–676
26. Glaser SM, Dohopolski MJ, Balasubramani GK et al (2017) Glioblastoma Multiforme (GBM) in the elderly: initial treatment strategy and overall survival. *J Neurooncol* 134. <https://doi.org/10.1007/s11060-017-2493-x>
27. Morgan ER, Norman A, Laing K, Seal MD (2017) Treatment and outcomes for glioblastoma in elderly compared with non-elderly patients: a population-based study. *Curr Oncol*. <https://doi.org/10.3747/co.24.3424>
28. Pretanvil JA, Salinas IQ, Piccioni DE (2017) Glioblastoma in the elderly: treatment patterns and survival. *CNS Oncol* 6. <https://doi.org/10.2217/cns-2016-0023>
29. Putz F, Putz T, Goerig N et al (2016) Improved survival for elderly married glioblastoma patients: better treatment delivery, less toxicity, and fewer Disease Complications. *Strahlenther Onkol* 192
30. Zhang C, Wang X, Hao S et al (2016) Analysis of treatment tolerance and Factors Associated with overall survival in Elderly patients with Glioblastoma. <https://doi.org/10.1016/j.wneu.2016.07.079>. *World Neurosurg* 95:
31. Socha J, Kepka L, Ghosh S et al (2016) Outcome of treatment of recurrent Glioblastoma Multiforme in elderly and/or frail patients. *J Neurooncol* 126. <https://doi.org/10.1007/s11060-015-1987-7>
32. Hegi ME, Diserens A-C, Gorlia T et al (2005) MGMT Gene silencing and benefit from Temozolomide in Glioblastoma. *N Engl J Med* 352. <https://doi.org/10.1056/nejmoa043331>
33. Hegi ME, Genbrugge E, Gorlia T et al (2019) MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: a pooled analysis of four clinical trials. *Clin Cancer Res*. <https://doi.org/10.1158/1078-0432.CCR-18-3181>. 25:
34. Stupp R, Ram Z (2017) OS07.9 Standard of care temozolomide chemotherapy ± Tumor treating fields (TTFields) in newly diagnosed glioblastoma. Final results of the phase III EF-14 clinical trial. *Neuro Oncol* 19. <https://doi.org/10.1093/neuonc/nox036.050>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.